Witryna1 dzień temu · IMpower133、CASPIAN两项III期研究先后取得阳性结果[16,17],并获批ES-SCLC适应症,开启了小细胞肺癌免疫治疗新纪元,中国自主研发的阿得贝利单抗CAPSTONE-1研究,进一步验证了PD-L1抑制剂在ES-SCLC中的标准治疗地位,研究结果荣登The Lancet Oncology,随着适应症的获批 ... Witryna28 cze 2024 · The IMpower133 trial [NCT02763579] looked at frontline patients with ES-SCLC, randomized 1:1 to atezolizumab, a PD-L1 inhibitor, in combination with EP for 4 cycles, followed by maintenance with atezolizumab until progression versus EP in combination with placebo, followed by maintenance with placebo.2 This was a double …
Updated Overall Survival and PD-L1 Subgroup Analysis of Patients …
Witryna28 wrz 2024 · MOORADIAN: The current National Comprehensive Cancer Network ES-SCLC guidelines, which were updated in [August], look at the preferred regimens based on both the IMpower133 trial [NCT02763579], which is carboplatin/etoposide/atezolizumab [Tecentriq], as well as the CASPIAN trial … Witryna26 wrz 2024 · In the IMpower133 double-blind, placebo-controlled, phase 3 trial, treatment-naïve patients with ES-SCLC and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 were randomized to receive EP (with carboplatin) with either atezolizumab or placebo for four 21-day cycles (induction phase) followed … minifs greater than cell reference
IMpower, CASPIAN, and more: exploring the optimal first-line
WitrynaINTRODUCTION. One of the standard first-line treatments for extensive-stage small cell lung cancer (ES-SCLC) has become a combination therapy of atezolizumab (an anti-programmed death ligand-1 [PD-L1] antibody), carboplatin (CBDCA), and etoposide (VP-16) because the IMpower133 trial has revealed that the addition of atezolizumab to … Witryna9 mar 2024 · IMpower133 is a randomized, multicenter, double-blind, placebo-controlled trial in which patients were randomized (1:1) to either atezolizumab in combination with etoposide and carboplatin (A+EC) or placebo in combination with … Witryna11 kwi 2024 · BackgroundProgrammed cell death-ligand 1 (PD-L1) inhibitors plus chemotherapy have made substantial progress in extensive-stage small-cell lung … most popular french names boys